Tagged with “Procrit”
ArchivesDingell to Companies…Stop Using “Misleading and Deceptive” Ads
House Energy and Commerce Committee Chair, John Dingell (D-MI) and Oversight Subcommittee Chair, Bart Stupak (D-MI) sent letters to Johnson & Johnson, Merck, Schering-Plough and Pfizer asking them to stop using “misleading and deceptive” direct-to-consumer advertising.
Dingell in a statement said, “Marketing department leaders have failed to commit to reducing misleading and deceptive ads, so we’re now asking the CEOs to make this agreement.” Stupak said, “We intend to make certain that drug companies market their product properly in order to protect American consumers from manipulative commercials designed to mislead and deceive for profit.”
Posted by Joe Arite on May 22nd, 2008
Posted in: Policy & Advocacy News | No Comments »
Tags: Congress, DTC, FDA, Johnson and Johnson, Procrit
House of Representatives’ Oversight Subcommittee Addresses Direct to Consumer Advertisements
The House Energy & Commerce Subcommittee on Oversight convened a hearing May 8th to address Direct to Consumer (DTC) drug advertising by Johnson and Johnson, Pfizer and Merck Schering-Plough. C3 first raised questions in summer 2007 about Procrit® DTC advertising that ran from 1998 to 2005. Procrit is an anemia drug sold by Ortho Biotech, a subsidiary of Johnson and Johnson.
Posted by Joe Arite on May 14th, 2008
Posted in: Policy & Advocacy News | 1 Comment »
Tags: Congress, DTC, FDA, Johnson and Johnson, Procrit
